Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Influenza vaccination is recommended for all persons who are 6 months of age and older according to the Advisory Committee on Immunization Practices (ACIP). Reducing the occurrence and transmission of disease through awareness and prevention efforts grounded in improved vaccination rates among the general population continues to be one of the most cost-effective approaches targeting infectious disease mitigation. Patient perceptions of influenza vaccine formulations and delivery systems available might influence their decision to receive the seasonal flu vaccine, thereby impacting vaccination rates. A number of different delivery systems and dosage formulations of influenza vaccine currently exist: Intramuscular (IM), Intranasal (IN), Intradermal (ID), and Needle-free IM injection (NF). Previous research has attempted to focus on the perceptions regarding tolerability of administration, risk, efficacy, and past experiences that guide preferences regarding dosage form selection